Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Imatinib Stories

2008-07-22 09:01:13

WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that improves exercise capacity by a greater percentage than Actelion's Tracleer at 16 weeks, would earn a 48 percent patient share in the treatment of pulmonary arterial hypertension, according to surveyed pulmonologists. Although other efficacy measures are also important to prescribers, they indicate that...

2008-07-02 09:00:13

Rationale: Platelet-derived growth factor (PDGF) promotes the proliferation and migration of pulmonary artery smooth muscle cells (PASMCs), and may play a role in the progression of pulmonary arterial hypertension (PAH), a condition characterized by proliferation of PASMCs resulting in the obstruction of small pulmonary arteries. Objectives: To analyze the expression and pathogenic role of PDGF in idiopathic PAH. Methods: PDGF and PDGF receptor mRNA expression was studied by real-time...

2008-07-01 09:01:11

ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today that it has submitted the non-clinical section of the rolling submission of a New Drug Application (NDA) for omacetaxine mepesuccinate (formerly known as Ceflatonin(R)) to the U.S. Food and Drug Administration (FDA). "The non-clinical section of the NDA is the first of three parts necessary to complete the NDA submission of omacetaxine and brings us one step closer to commercialization," said Dr. Greg Collier, ChemGenex's...

2008-06-24 02:30:28

U.S. and Swedish researchers say a leukemia drug may help patients benefit from tissue plasminogen activator, or tPA stroke treatment. For more than a decade, the drug tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke but its promise is blemished because: tPA can cause dangerous bleeding in the brain and its brain-saving power fades fast after the third hour of a stroke. Researchers at the University of Michigan and the Ludwig Institute...

2008-06-22 15:00:28

ANN ARBOR, Mich., June 22 /PRNewswire-USNewswire/ -- For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke. Now, a new paper published online in Nature Medicine reveals why tPA has these limitations. It also gives tantalizing evidence about how...

2008-06-16 12:01:05

Exelixis has reported preliminary Phase I data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia who are resistant to or intolerant of the approved BCR-ABL inhibitors imatinib and dasatinib. Approximately 17 subjects have received at least one dose of XL228, of whom 16 had completed cycle 1. The trial is evaluating a treatment cycle consisting of four weekly one-hour IV infusions of XL228 at doses...

2008-06-16 09:01:19

ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today the presentation of positive preliminary results from a phase 2 study of omacetaxine mepesuccinate (formerly known as Ceflatonin(R)) in chronic myeloid leukemia (CML) patients who have failed therapy with at least two tyrosine kinase inhibitors (TKIs). These data represent the first findings to be presented from this ongoing study, conducted in patients with or without BCR-ABL mutations. The data presented complement the...

2008-06-09 06:00:38

Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic analysis solutions, today announced that Portland, Ore.-based Oregon Health & Science University (OHSU) Cancer Institute has purchased a MassARRAY(R) system for use in the discovery, development and testing of biomarker panels for rapid classification and characterization of cancer. The OHSU Cancer Institute is recognized worldwide for its cancer research. "This placement at the prestigious OHSU Cancer Institute is a tremendous...

2008-06-05 03:00:07

By Edwards, Michael A Beatty, John S; Shah, Malay B; Bittner, James G IV To the Editor: Non-epithelial mesenchymal tumors, including gastrointestinal stromal tumors (GISTs) and smooth muscle tumors (SMTs), are rare and may occur in any part of the alimentary tract.1 GISTs originate from the interstitial cell of Cajal, an intestinal pacemaker cell, and represent 1 per cent to 3 per cent of all gastrointestinal malignant tumors. Approximately 5 per cent of GISTs occur in the colon and rectum...

632e85fdf2a7b2b8406f7bac0448b4db
2008-03-06 10:30:00

According to new research, use of the cancer drug Gleevec may cause fertility complications in some women.Dr. Constantinos Christopoulos of the Amalia Fleming General Hospital in Athens and colleagues published the recent study of the drug, generically known as imatinib, in the New England Journal of Medicine. The team studied the case of a 30-year-old woman with chronic myeloid leukemia (CML). After taking Gleevec for two years, the woman stopped menstruating. They also noted a reduction of...